Fuze, a cloud-based communications solution provider for the modern global enterprise, has been selected by Ascendis Pharma to create a modern communications infrastructure that will support the rapidly growing biotech firm in its collaboration with multiple research partners, manufacturers, and clinical trial specialists worldwide, the company said.
Listed on the NASDAQ with a market cap of almost USD 1 billion, Ascendis Pharma is a biopharmaceutical company focused on advancing a pipeline of long-acting prodrug therapies. The company operates out of a research facility in Heidelberg, Germany with sites in Palo Alto, Calif. and Copenhagen, Denmark. Outsourcing manufacturing, clinical studies, and research to partners in the biopharmaceutical sector is a key strategy, which makes effective collaboration vital.
Fuze replaces a web conferencing system that offered limited functionality with a completely unified communications platform. In one application, Fuze integrates chat, presence, voice, and HD video to allow seamless communication both within Ascendis Pharma and externally to its biopharmaceutical partners. Unlike the existing web conferencing tool, partners and suppliers can participate in any Fuze meeting with ease, without a complicated process when downloading and installing an app to attend every online meeting.
Fuze is a global, cloud-based unified communications platform that empowers productivity and delivers insights across the enterprise by enabling simplified business voice communications, flexible video conferencing, and always-on collaboration. Formerly ThinkingPhones, Fuze allows the modern, mobile workforce to seamlessly communicate anytime, anywhere, across any device. Headquartered in Boston, MA, Fuze has additional locations including New York, San Francisco, Seattle, Ottawa, London, Amsterdam, Aveiro (Portugal), Paris, Munich, Zurich, Madrid, Copenhagen, and Sydney.